Liprolog

Riik: Euroopa Liit

keel: inglise

Allikas: EMA (European Medicines Agency)

Osta kohe

Infovoldik Infovoldik (PIL)
30-01-2023
Toote omadused Toote omadused (SPC)
30-01-2023
Avaliku hindamisaruande Avaliku hindamisaruande (PAR)
18-03-2020

Toimeaine:

insulin lispro

Saadav alates:

Eli Lilly Nederland B.V.

ATC kood:

A10AB04, A10AD04

INN (Rahvusvaheline Nimetus):

insulin lispro

Terapeutiline rühm:

Drugs used in diabetes

Terapeutiline ala:

Diabetes Mellitus

Näidustused:

For the treatment of adults and children with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. Liprolog is also indicated for the initial stabilisation of diabetes mellitus.

Toote kokkuvõte:

Revision: 30

Volitamisolek:

Authorised

Loa andmise kuupäev:

2001-08-01

Infovoldik

                                104
B. PACKAGE LEAFLET
105
PACKAGE LEAFLET: INFORMATION FOR THE USER
LIPROLOG 100 UNITS/ML SOLUTION FOR INJECTION IN VIAL
insulin lispro
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
:
1.
What Liprolog is and what it is used for
2.
What you need to know before you use Liprolog
3.
How to use Liprolog
4.
Possible side effects
5.
How to store Liprolog
6.
Contents of the pack and other information
1.
WHAT LIPROLOG IS AND WHAT IT IS USED FOR
Liprolog is used to treat diabetes. Liprolog works more quickly than
normal human insulin because
the insulin molecule has been changed slightly.
You get diabetes if your pancreas does not make enough insulin to
control the level of glucose in your
blood. Liprolog is a substitute for your own insulin and is used to
control glucose in the long term. It
works very quickly and lasts a shorter time than soluble insulin (2 to
5 hours). You should normally
use Liprolog within 15 minutes of a meal.
Your doctor may tell you to use Liprolog as well as a longer-acting
insulin. Each kind of insulin
comes with another patient information leaflet to tell you about it.
Do not change your insulin unless
your doctor tells you to. Be very careful if you do change insulin.
Liprolog is suitable for use in adults and children.
2.
WHAT YOU NEED TO KNOW BEFORE YOU USE LIPROLOG
DO NOT USE LIPROLOG
-
if you think
HYPOGLYCAEMIA
(low blood sugar) is starting. Further in this leaflet it tells you
how to
deal with mild hypoglycaemia (see Section 3: If you take more Liprolog
than you need).
-
if you 
                                
                                Lugege kogu dokumenti
                                
                            

Toote omadused

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Liprolog 100 units/ml, solution for injection in vial
Liprolog 100 units/ml, solution for injection in cartridge
Liprolog 100 units/ml KwikPen, solution for injection in a pre-filled
pen
Liprolog 100 units/ml Junior KwikPen, solution for injection in a
pre-filled pen
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml contains 100 units insulin lispro* (equivalent to 3.5mg).
Vial
Each vial contains 1000 units of insulin lispro in 10 ml solution.
Cartridge
Each cartridge contains 300 units of insulin lispro in 3 ml solution.
KwikPen
Each pre-filled pen contains 300 units of insulin lispro in 3 ml
solution.
Each KwikPen delivers 1-60 units in steps of 1 unit.
Junior KwikPen
Each pre-filled pen contains 300 units of insulin lispro in 3 ml
solution.
Each Junior KwikPen delivers 0.5 – 30 units in steps of 0.5 units.
*produced in
_E.coli_
by recombinant DNA technology.
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Solution for injection.
Clear, colourless, aqueous solution.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
For the treatment of adults and children with diabetes mellitus who
require insulin for the maintenance
of normal glucose homeostasis. Liprolog is also indicated for the
initial stabilisation of diabetes
mellitus.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
The dosage should be determined by the physician, according to the
requirement of the patient.
_Junior KwikPen _
Liprolog 100 units/ml Junior KwikPen is suitable for patients who may
benefit from finer insulin dose
adjustments.
Liprolog may be given shortly before meals. When necessary Liprolog
can be given soon after meals.
3
Liprolog takes effect rapidly and has a shorter duration of activity
(2 to 5 hours) given subcutaneously
as compared with soluble insulin. This rapid onset of activity allows
a Liprolog injection (or, in the
case of administration by continuous subcutaneous infusion, a Liprolog
bolus) to be given very close
to 
                                
                                Lugege kogu dokumenti
                                
                            

Dokumendid teistes keeltes

Infovoldik Infovoldik bulgaaria 30-01-2023
Toote omadused Toote omadused bulgaaria 30-01-2023
Avaliku hindamisaruande Avaliku hindamisaruande bulgaaria 18-03-2020
Infovoldik Infovoldik hispaania 30-01-2023
Toote omadused Toote omadused hispaania 30-01-2023
Avaliku hindamisaruande Avaliku hindamisaruande hispaania 18-03-2020
Infovoldik Infovoldik tšehhi 30-01-2023
Toote omadused Toote omadused tšehhi 30-01-2023
Avaliku hindamisaruande Avaliku hindamisaruande tšehhi 18-03-2020
Infovoldik Infovoldik taani 30-01-2023
Toote omadused Toote omadused taani 30-01-2023
Avaliku hindamisaruande Avaliku hindamisaruande taani 18-03-2020
Infovoldik Infovoldik saksa 30-01-2023
Toote omadused Toote omadused saksa 30-01-2023
Avaliku hindamisaruande Avaliku hindamisaruande saksa 18-03-2020
Infovoldik Infovoldik eesti 30-01-2023
Toote omadused Toote omadused eesti 30-01-2023
Avaliku hindamisaruande Avaliku hindamisaruande eesti 18-03-2020
Infovoldik Infovoldik kreeka 30-01-2023
Toote omadused Toote omadused kreeka 30-01-2023
Avaliku hindamisaruande Avaliku hindamisaruande kreeka 18-03-2020
Infovoldik Infovoldik prantsuse 30-01-2023
Toote omadused Toote omadused prantsuse 30-01-2023
Avaliku hindamisaruande Avaliku hindamisaruande prantsuse 18-03-2020
Infovoldik Infovoldik itaalia 30-01-2023
Toote omadused Toote omadused itaalia 30-01-2023
Avaliku hindamisaruande Avaliku hindamisaruande itaalia 18-03-2020
Infovoldik Infovoldik läti 30-01-2023
Toote omadused Toote omadused läti 30-01-2023
Avaliku hindamisaruande Avaliku hindamisaruande läti 18-03-2020
Infovoldik Infovoldik leedu 30-01-2023
Toote omadused Toote omadused leedu 30-01-2023
Avaliku hindamisaruande Avaliku hindamisaruande leedu 18-03-2020
Infovoldik Infovoldik ungari 30-01-2023
Toote omadused Toote omadused ungari 30-01-2023
Avaliku hindamisaruande Avaliku hindamisaruande ungari 18-03-2020
Infovoldik Infovoldik malta 30-01-2023
Toote omadused Toote omadused malta 30-01-2023
Avaliku hindamisaruande Avaliku hindamisaruande malta 18-03-2020
Infovoldik Infovoldik hollandi 30-01-2023
Toote omadused Toote omadused hollandi 30-01-2023
Avaliku hindamisaruande Avaliku hindamisaruande hollandi 18-03-2020
Infovoldik Infovoldik poola 30-01-2023
Toote omadused Toote omadused poola 30-01-2023
Avaliku hindamisaruande Avaliku hindamisaruande poola 18-03-2020
Infovoldik Infovoldik portugali 30-01-2023
Toote omadused Toote omadused portugali 30-01-2023
Avaliku hindamisaruande Avaliku hindamisaruande portugali 18-03-2020
Infovoldik Infovoldik rumeenia 30-01-2023
Toote omadused Toote omadused rumeenia 30-01-2023
Avaliku hindamisaruande Avaliku hindamisaruande rumeenia 18-03-2020
Infovoldik Infovoldik slovaki 30-01-2023
Toote omadused Toote omadused slovaki 30-01-2023
Avaliku hindamisaruande Avaliku hindamisaruande slovaki 18-03-2020
Infovoldik Infovoldik sloveeni 30-01-2023
Toote omadused Toote omadused sloveeni 30-01-2023
Avaliku hindamisaruande Avaliku hindamisaruande sloveeni 18-03-2020
Infovoldik Infovoldik soome 30-01-2023
Toote omadused Toote omadused soome 30-01-2023
Avaliku hindamisaruande Avaliku hindamisaruande soome 18-03-2020
Infovoldik Infovoldik rootsi 30-01-2023
Toote omadused Toote omadused rootsi 30-01-2023
Avaliku hindamisaruande Avaliku hindamisaruande rootsi 18-03-2020
Infovoldik Infovoldik norra 30-01-2023
Toote omadused Toote omadused norra 30-01-2023
Infovoldik Infovoldik islandi 30-01-2023
Toote omadused Toote omadused islandi 30-01-2023
Infovoldik Infovoldik horvaadi 30-01-2023
Toote omadused Toote omadused horvaadi 30-01-2023
Avaliku hindamisaruande Avaliku hindamisaruande horvaadi 18-03-2020

Otsige selle tootega seotud teateid

Vaadake dokumentide ajalugu